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Epigenetic Modifications in Schizophrenia and
Related Disorders: Molecular Scars of
Environmental Exposures and Source of
Phenotypic Variability
Juliet Richetto and Urs Meyer
ABSTRACT
Epigenetic modifications are increasingly recognized to play a role in the etiology and pathophysiology of schizo-
phrenia and other psychiatric disorders with developmental origins. Here, we summarize clinical and preclinical
findings of epigenetic alterations in schizophrenia and relevant disease models and discuss their putative origin.
Recent findings suggest that certain schizophrenia risk loci can influence stochastic variation in gene expression
through epigenetic processes, highlighting the intricate interaction between genetic and epigenetic control of neu-
rodevelopmental trajectories. In addition, a substantial portion of epigenetic alterations in schizophrenia and related
disorders may be acquired through environmental factors and may be manifested as molecular “scars.” Some of
these scars can influence brain functions throughout the entire lifespan and may even be transmitted across gen-
erations via epigenetic germline inheritance. Epigenetic modifications, whether caused by genetic or environmental
factors, are plausible molecular sources of phenotypic heterogeneity and offer a target for therapeutic interventions.
The further elucidation of epigenetic modifications thus may increase our knowledge regarding schizophrenia’s
heterogeneous etiology and pathophysiology and, in the long term, may advance personalized treatments through
the use of biomarker-guided epigenetic interventions.
https://doi.org/10.1016/j.biopsych.2020.03.008
Schizophrenia is a chronic and severe mental disorder that
affects approximately 1 in 100 individuals worldwide (1). It is
characterized by varying degrees of cognitive impairments,
emotional aberrations, and behavioral anomalies, which
together undermine basic processes of perception, reasoning,
and judgment. Typically, the onset of full-blown schizophrenia
is in early adulthood and includes a myriad of symptoms,
which are referred to as positive symptoms (e.g., visual and/or
auditory hallucinations, delusions, paranoia, psychomotor
agitation), negative symptoms (e.g., social withdrawal, apathy,
deficits in motivation and reward-related functions), and
cognitive symptoms (e.g., deficits in executive functioning,
working memory, and attention) (2).
The etiology of schizophrenia is likely to be multifactorial,
with multiple small-effect and fewer large-effect susceptibility
genes interacting with several environmental factors (2–4). The
combination of genetic and environmental risk factors is
believed to affect the normal course of brain development
and maturation, manifesting in a cascade of neurotransmitter
and circuit dysfunctions and impaired connectivity in
early adulthood (5,6). While common and rare genetic abnor-
malities provide the basis for the substantial heritability of
schizophrenia, environmental factors may contribute to the
disorder’s etiology partly through epigenetic processes (7,8).
The latter are commonly referred to as the combination of
mechanisms that confer short- and long-term changes in gene
expression without altering the DNA code itself (7,8).
Epigenetic processes include several interrelated mechanisms
such as chromatin remodeling, histone modifications, DNA
methylation (DNAm), and expression of noncoding RNAs
(ncRNAs) (Figure 1 and Supplement). The orchestrated action
of these epigenetic processes has a considerable influence on
gene expression and may further provide a basis for trans-
generational nongenetic inheritance of environmentally ac-
quired traits (9).
While epigenetic processes have long been speculated to
contribute to monozygotic twin discordance (10), their impor-
tance is increasingly recognized for virtually every aspect of
normal and pathological brain development and functioning
(11). Not only may epigenetic processes mediate the effects of
environmental risk in schizophrenia and other multifactorial
neuropsychiatric disorders, but also they can interact with the
genomic risk associated with these disorders (12,13). Hence,
the exploration of epigenetic modifications holds the promise
of new discoveries at the crossroads of genes and environ-
ment. In this review article, we summarize clinical and
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preclinical findings of epigenetic alterations in schizophrenia
and relevant disease models and discuss their putative origin.
We also speculate how such modifications may contribute to
pathological trait variability and offer avenues for novel
treatments.
EPIGENETIC MODIFICATIONS IN SCHIZOPHRENIA
DNA Methylation
Alterations in DNAm were among the first epigenetic modifi-
cations to be associated with schizophrenia. Pioneering work
conducted by Costa, Guidotti, Grayson, and colleagues indi-
cated that reduced transcription of the extracellular matrix
protein reelin (RELN) in the brains of people with schizophrenia
might be caused by hypermethylation of its promoter region
(14–16). This notion was further supported by findings showing
that patients with schizophrenia display increased cortical and
subcortical expression of DNMT1 (17,18), which primarily
functions to maintain DNAm at CpG sites (19). In addition to
RELN, numerous other (historical) candidate risk genes for
schizophrenia were found to be differentially methylated,
including genes involved in gamma-aminobutyric acidergic
(GABAergic) (GAD1) functions (20), dopaminergic (DRD2,
DRD3, COMT, IGF2) functions (10,21–27), serotonergic
(HTR2A) functions (28,29), and oligodendrocyte (SOX10)
functions (30,31). However, some of these initial findings could
not be replicated (32,33), which is likely explained by the use of
small sample sizes and/or differences in the methods used to
quantify DNAm in postmortem samples, with initial studies
lacking technological sensitivity as compared with contem-
porary methods.
As a counterpart to targeted approaches, technical and
theoretical advances have recently facilitated DNAm profiling
across the entire genome (Table 1). These studies are based
on sample sizes that range among 10 (34–37), 20 to 40
(32,38–44), and more than 60 (45–47) patients and control
subjects. They are mostly based on the Infinium Human
Methylation 450K BeadChip, which allows the user to assess
more than 450,000 CpGs located throughout the genome, and
they mainly focus on the prefrontal cortex (PFC)
(32,34,37–39,41,42,44–47), the hippocampus (35–37,42), and,
to a lesser extent, the striatum (42,43), cerebellum (38,40,42),
and anterior cingulate cortex (37). The largest study to date,
performed by Jaffe et al. (47), identified 2104 differentially
methylated CpGs in the PFC of subjects with schizophrenia
relative to control subjects. The differentially methylated CpGs
were found to be enriched in genes relevant for embryonic
development, cell fate commitment, and nervous system dif-
ferentiation. The authors also observed that the epigenetic
landscape, as represented by DNAm, varied markedly across
Figure 1. Schematic representation of chromatin
structure and major epigenetic processes. The DNA–
protein complex within chromosomes is referred to
as chromatin. The functional unit of the chromatin is
the nucleosome (not shown), which is composed of
DNA wrapped around a core octamer of histone
proteins. The DNA–histone interaction occurs at the
N-terminal tails of these histones, which provide
sites for epigenetic marks known as histone modifi-
cations. A number of histone modifications exist,
including methylation (me), acetylation (ac), phos-
phorylation (pho), ubiquitination (ub), and SUMOyla-
tion (sum). Histone modifications determine the
extent to which chromatin is wrapped around his-
tone proteins. Loosely coiled chromatin contains
transcriptionally accessible DNA regions, whereas
tightly coiled chromatin comprises transcriptionally
inactive DNA regions. DNA methylation refers to the
covalent modification of the DNA at position 50 in the
cytosine ring (5mC), which is found primarily at CpG
dinucleotides. 5mC (and other methylation-related
epigenetic marks) can also exist at non-CpG sites
(not shown). Whereas 5mC is established and
maintained by methyltransferases (DNMTs), it is
oxidized by the TET family of dioxygenase proteins
to 5-hydroxymethylcytosine (5hmC). In successive
steps, TET enzymes further hydroxylate 5hmC to
generate 5-formylcytosine (5fC) and 5-
carboxylcytosine (5caC). Whereas 5fC and 5caC
are recognized and removed by TDG, the created
abasic site is repaired by the BER pathway, gener-
ating an unmodified cytosine. Besides epigenetic
modifications at histone proteins and DNA, non-
coding RNAs provide an additional level of epige-
netic regulation involved in chromatin and nuclear remodeling, gene transcription, translational repression, and degradation of messenger RNAs. Based on
their size, noncoding RNAs can be broadly subdivided into lncRNAs (.200 nucleotides) and sncRNAs (,200 nucleotides), the latter of which contain small
inhibiting RNAs, microRNAs, PIWI-interacting RNAs, and small nuclear RNAs (not shown). BER, base excision repair; DNMT, DNA methyltransferase; lncRNAs,
long noncoding RNAs; sncRNAs, short noncoding RNAs; TDG, thymine-DNA glycosylase; TET, ten-eleven translocation.
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development, possibly mirroring shifts in neuronal composition
across the lifespan and age-dependent changes in gene
expression profiles. Interestingly, schizophrenia risk loci were
primarily enriched for loci expressing these shifting epigenetic
states, particularly those that change during the transition from
prenatal to postnatal life. Together, these data implicate an
epigenetic component to the developmental origins of
schizophrenia and suggest that there is an early epigenetic
intermediate between genetically and biologically determined
risks for the disorder (47).
There is also an increasing number of genome-wide DNAm
profiling studies of non–central nervous system (CNS) tissues
such as blood (12,13,48–53) and saliva (54) (Table 2). These
can be further subdivided into longitudinal studies (48–51,54),
which assessed markers of conversion to psychosis in twins
discordant for schizophrenia or high-risk individuals, and
biomarker studies (12,13,52,53), which aim at uncovering
biomarkers for schizophrenia in large cohorts. One advantage
of such studies is that they provide a means to perform
noninvasive and longitudinal epigenetic examinations, which
Table 1. Genome-wide DNA Methylation Changes in Schizophrenia: Brain Tissue
Sample Brain Region Method Most Significant Reference
35 SZ and 35 CTR FC CpG island microarray Male subjects: EXOSC7, GRIA2, ELMOD1, KCNJ6,
WDR18
Female subjects: C6orf84, HCG9, SLC17A7, NR4A2,
AB051500
(32)
20 SZ and 23 CTR PFC (London) 450K array GSDMD, RASA3, HTR5A, PPFIA1, CACNA1G (from DMPs
associated with SZ)
(38)
21 SZ and 23 CTR CBL (London) ANO4, NRN1, PPAPDC1B, NAIF1, SNX26 (from DMRs
associated with SZ)
18 SZ and 15 CTR PFC (Montreal) NAV1, ZNF200, PRH2, NFIA, COL16A1 (from DMPs
associated with SZ)
24 SZ and 24 CTR PFC 450K array TNR6C6, C21orf33, HOXA11, CCNI, HOXA13, NOS1,
AKT1, DNMT1, SOX10, DTNBP1, PPP3CC
(39)
106 SZ and 110 CTR DLPFC 27K array ASTN2, IL1RL1, GRIA4, LRRIQ2, SH2BP1, ABCB1,
CEACAM19
(45)
39 SZ and 43 CTR CBL 27K array PIK3R1, BTN3A3, NHLH1, SLC16A7 (40)
62 SZ and 62 CTR PFC 450K array CERS3, DPPA5, PRDM9, DDX43, REC8, LY6G5C (DMRs) (46)
5 SZ and 6 CTR PFC MeDIP-seq
RNA-seq
PLP1, NR4A1, IL1B, GFAP, APC, TAAR1, MYT1L, GRIP1,
ASTN2, EGFR, CD28, SLC6A2
(34)
8 SZ and 8 CTR H (CA1 vs. CA2/3) 450K array MSX1, DAXX, CCND2, FOXG1, GAD1 (35)
19 SZ and 3 CTR H 450K array NUBP1, STK32B, AIG1, PRKCE, RASA3 (37)
DLPFC HLA-DQA1, HCN2, AJAP1, HLA-B, HLA-DRB5
ACC C4orf50, GALNT1, VSX2, SAPS2, KCNK7
108 SZ and 136 CTR DLPFC 450K array CD164, COPZ2, SUGT1, HAT1, TYW1B (47)
26 SZ and 27 CTR PFC MBD-seq FOXP1, IL1RAP, AKAP13, SLC39A11, RPTOR (41)
38 SZ and 38 CTR PFC 450K array NCAM1, SND1, LILRB1, GSDMD, ABTB (42)
37 SZ and 45 CTR STR SYNPO, HECW1, GRINL1A, DEFB115, GBP4
14 SZ and 13 CTR H ATP6V0D, CACNA1G, RBM24, ZCCHC10, RASIP1
37 SZ and 40 CTR CBL GART, ELK3, PDX1, ZNF586, ZNF217
8 SZ and 8 CTR H (GABAergic interneurons) 450K array SLC7A6 (36)
22 SZ and 22 CTR STG 450K array DLG1 (or BDH1), SERGET, TPGS2, CLEC16A, AHRR;
BAIAP2, and DLG1 strongly associated with dendritic
spine density
(43)
23 SZ and 27 CTR Brodmann area 46 WGBS Cell type–specific whole-genome methylomes from
neurons and oligodendrocytes obtained from SZ and
CTR; DNA methylation differences tended to occur in
cell type differentially methylated sites. 97 DM CpGs (14
NeuN1 and 83 OLIG21 specific). Top NeuN1: FSTL5,
GNA14, ERC2, LHFPL2, OSBPL6. Top OLIG21:
PPP1R9A, CHN2, CBLN4, TRIM49B, MGC32805
(44)
The table summarizes the main findings from studies assessing genome-wide DNA methylation profiles in brain tissue of patients with
schizophrenia (SZ) relative to matched control subjects (CTR) and/or in subjects at high risk for psychosis relative to control subjects. The table
specifies the study sample, brain region, method used to assess DNA methylation profiles, and genes and loci with the most significant DNA
methylation changes.
ACC, anterior cingulate cortex; CA, cornu ammonis subfield of hippocampus; CBL, cerebellum; DMP, differentially methylated position; DMR,
differentially methylated region; DLPFC, dorsolateral prefrontal cortex; FC, frontal cortex; GABAergic, gamma-aminobutyric acidergic; H,
hippocampus; MBD-seq, methyl-CpG binding domain protein-enriched genome sequencing; MeDIP-seq, methylated DNA immunoprecipitation
sequencing; PFC, prefrontal cortex; RNA-seq, RNA sequencing; STG, superior temporal gyrus; STR, striatum; WGBS, whole genome bisulfate
sequencing.
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would not be possible using brain tissue. Peripheral epigenetic
profiling, however, does not necessarily capture disease-
associated epigenetic changes occurring in the CNS. In sup-
port of the latter notion, there is only minimal overlap between
the findings obtained by genome-wide DNAm profiling in CNS
and non-CNS tissues of schizophrenia (Tables 1 and 2).
Hence, while peripheral epigenetic profiling may still be valid
for the identification of molecular biomarkers, it appears that
peripheral epigenetic signatures do not grossly mirror those in
the CNS and vice versa.
The assay for transposase-accessible chromatin using
sequencing (ATAC-seq) is a powerful addition to the genome-
wide DNAm profiling approaches because it allows re-
searchers to assess genome-wide chromatin accessibility
and overall changes in epigenetic landscapes and corre-
sponding gene signatures (55). ATAC-seq has recently been
implemented in schizophrenia research (56,57) and has
already provided preliminary evidence for altered chromatin
accessibility in schizophrenia cases compared with control
cases. For example, performing ATAC-seq on adult PFC
brain samples from 135 individuals with schizophrenia and
137 control subjects, Bryois et al. (56) found that chromatin
accessibility in schizophrenia differs in three specific genomic
regions. Moreover, the authors identified 118,152 ATAC-seq
peaks in PFC tissue, many of which were found to be
enriched for schizophrenia single nucleotide polymorphism
heritability (56). Further use of ATAC-seq is expected to
provide imperative new knowledge regarding the molecular
mechanisms of altered gene expression in schizophrenia and
beyond.
Histone Modifications
Several lines of evidence suggest that histone post-
translational modifications (PTMs) play a role in the etiology
and pathophysiology of schizophrenia. Initial support for this
notion stemmed from the observation that valproate, a mood
stabilizer with frequent off-label use in schizophrenia (58), is a
histone deacetylase (HDAC) inhibitor when administered at
therapeutic doses (59). Based on the findings showing bene-
ficial effects of valproate on clinical symptoms in some pa-
tients with schizophrenia (60), various studies explored
whether schizophrenia is linked to specific histone PTMs and
associated alterations in the enzymes that catalyze such
modifications. The existing evidence for such alterations in-
cludes the presence of high levels of H3R17 methylation (61),
increased cortical levels of HDAC1 (62,63), and histone
methyltransferases (64,65), but reduced cortical levels of
HDAC2 (66) in postmortem samples of cases with schizo-
phrenia. The latter finding was recently corroborated by an
in vivo positron emission tomography study using a radiotracer
version of the potent HDAC inhibitor [11C]Martinostat, showing
Table 2. Genome-wide DNA Methylation Changes in Schizophrenia: Peripheral Tissue
Sample Tissue Type Method Most Significant Reference
Longitudinal Studies
11 MZ twin pairs discordant for SZ Whole blood 27K array PUS3, SYNGR2, KDELR1, PDK3, PPARGC1A (48)
2 MZ twin pairs discordant for SZ Whole blood NimbleGen
720K array
HIST2H2AA3, HIST2H2AA4, HIST2H3A,
HIST2H3Ac AK2 (pair 1)
DVL1, KIAA1751, CEP104, DFFB, CAMTA1 (pair 2)
(49)
24 MZ twin pairs discordant for psychotic
symptoms at 12 years of age
Buccal cells 450K array C5orf42, MORF4L1, GALNTL4, LOC340094, DIP2C (54)
14 converters and 25 nonconverters to
psychosis
Whole blood 450K array NRPI1, CHL1, EPHNA3, IL17RE, AKT1 (50)
767 subjects with psychotic episodes at 12
and 18 years of age (ALSPAC cohort)
Cord blood and
whole blood at
7 and 15 to 17
years of age
450K array BAIAP2, F2RL1, FAM19A5, FGFR3, LFNG, LPR5,




759 SZ and 738 CTR discovery cohort; 178 SZ
and 182 CTR replication cohort 1; 561 SZ
and 582 CTR replication cohort 2
Whole blood MBD-seq FAM63B, ARHGAP26, CTAGE11P, TBC1D22A,
RELN (replicated in all cohorts)
(52)
353 SZ and 322 CTR discovery cohort; 414 SZ
and 433 CTR replication cohort
Whole blood 450K array FAM126A, PPTC7, GYG1, SIK3, USP36 (part of 25
DMPs replicated also in the second cohort)
(12)
689 SZ and 645 CTR discovery cohort; 247 SZ
and 250 CTR replication cohort
Whole blood 450K array RPS6KA1, MGRN1, S100A2, NCOR, KIAA0355
(part of the top 15 replicated in all cohorts)
(13)
130 adolescents at risk for psychiatric
disorders, discovery cohort; 93
adolescents, replication cohort
Whole blood 450K array 305,147 CpG loci investigated in relation to 37 SNPs
associated with psychiatric disorders. 5 SNPs (in
HCRTR1, GAD1, HDAC3, and FKBP5) associated
with 7 DMPs (closest gene PEF1, GAD1, DIAPH1,
PCDHGC3, TULP1, and C11orf9)
(53)
The table summarizes the main findings from studies assessing genome-wide DNA methylation profiles in peripheral tissues of patients with
schizophrenia (SZ) relative to matched control subjects (CTR) and/or in subjects at high risk for psychosis relative to control subjects. The table
specifies the study sample, type of peripheral tissue, method used to assess DNA methylation profiles, and genes and loci with the most
significant DNA methylation changes.
ALSPAC, Avon Longitudinal Study of Parents and Children; DMP, differentially methylated position; MBD-seq, methyl-CpG binding domain
protein-enriched genome sequencing; MZ, monozygotic; SNP, single nucleotide polymorphism.
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lower in vivo HDAC levels in cases with schizophrenia as
compared with matched control subjects (67). Furthermore,
this study revealed a positive correlation between cortical
HDAC levels and cognitive performance independent of diag-
nostic groups (67), highlighting a general involvement of
HDACs in cognitive functions.
Imperative new research efforts, mainly fueled by the Psy-
chENCODE initiative (68), are also being made to comprehen-
sively map histone PTMs across the genome in different brain
regions, cell types, and psychiatric disorders. This initiative aims
at providing a public resource of genomic data (including histone
PTMs) originating from tissue and cell-specific samples of 1866
individuals (558 of whom were diagnosed with schizophrenia).
Based on the practical guidelines for chromatin immunoprecipi-
tation sequencing followed by deep sequencing suggested by
Kundakovic et al. (69), which ensure a high degree of standardi-
zation across studies, two studies investigated genome-wide
histone PTMs in health and disease. In a first study, Girdhar
et al. (70) profiled open chromatin-associated modifications in
neuronal and nonneuronal cells isolated from the dorsolateral
PFC and the anterior cingulate cortex of healthy subjects. These
investigations aimed at generating reference maps for two his-
tone marks (H3K4me3 and H3K27ac) that are associated with
active promoters and enhancers, which in turn can be used as a
resource tomaphistonePTMs inacell-type-specificmanner. The
results obtained by Girdhar et al. (70) show that neuronal and
nonneuronal cell types strongly differ with regard to histone
modification profiles, highlighting the critical role of cell-type-
specific epigenetic signatures in cortical tissue. Moreover, the
study found that risk variants for schizophrenia were over-
represented in neuronal versus nonneuronal H3K4me3 and
H3K27ac landscapes (70), emphasizing the need to focus on
neuronal populations for future investigations of histone PTMs in
this disorder.
In a second study, Wang et al. (71) annotated active en-
hancers (defined as open chromatin regions depleted in
H3K4me3 and enriched in H3K27ac) in neuronal and non-
neuronal nuclei originating from healthy individuals and pa-
tients with schizophrenic. This impressive dataset was used
to calculate chromatin quantitative trait loci and integrated
with other genomic data to obtain regulatory networks linking
enhancers, transcription factors, and target genes. These
regulatory networks were then further used to link schizo-
phrenia genome-wide association study variants to genes
(uncovering a set of 321 novel high-confidence schizo-
phrenia-associated genes) and finally embedded into a deep
learning model to predict psychiatric phenotypes from
genomic data, which provides a 6-fold increased improve-
ment in prediction over additive polygenic risk scores
(PRSs) (71).
A few studies further identified altered histone PTMs in
peripheral tissues from patients with schizophrenia. For
example, reduced acetylated H3 levels (72) and higher levels of
H3K9me2 (73) were found in lymphocytes obtained from pa-
tients relative to control subjects. Intriguingly, increased
H3K9me2 levels were also found in the parietal cortex of
schizophrenia cases (64,65), suggesting that there is a certain
correspondence between altered histone PTMs in peripheral
and central tissues.
Noncoding RNAs
The majority of studies examining the possible involvement of
ncRNAs in schizophrenia have focused on microRNAs (miR-
NAs) as opposed to other ncRNAs (34,74,75). A likely reason
for the strong focus on miRNAs is that a microdeletion at
chromosome 22q11.2, which is a genetic variation conferring
high risk of schizophrenia and other neurodevelopmental dis-
orders, includes a gene (DGCR8) encoding for an miRNA
processing protein (76). This discovery led to the hypothesis
that miRNA dysfunctionalities, whether induced by genetic or
environmental factors, are involved in the etiology and patho-
physiology of schizophrenia (77). Since the seminal findings of
Perkins et al. (78), who were the first to identify altered miRNA
profiles in postmortem PFC from patients with schizophrenia, a
number of studies revealed altered cortical and subcortical
expression of various miRNAs, including mir130 (79), mir181b
(80), mir497 (81), mir185 (82), mir9 (83), mir195, mir301a (84),
mir132, mir1307 (75), and mir137 (85). Notably, mir137 was
found to be linked to schizophrenia in an early genome-wide
association study (86), a finding that was confirmed in the
largest genome-wide association study of schizophrenia
existing to date (4). In further support of its involvement in
schizophrenia, mir137 represents an important signaling node
in various gene networks relevant to brain development and
functions, including axon guidance signaling, ephrin receptor
signaling, and synaptic activity (87,88), all of which are known
to be disrupted in schizophrenia and related disorders (2–5).
miRNAs have also been profiled in the blood of patients with
schizophrenia (89), with the main aim of identifying blood
biomarkers of the disease. In a recent genome-wide expres-
sion study, Du et al. (90) found that several miRNAs were
differentially expressed in serum exosomes of patients with
first-episode, drug-free schizophrenia relative to matched
control subjects. Importantly, among the differentially
expressed miRNAs, 11 could be used to dissociate schizo-
phrenia samples from control samples with 75% to 90% ac-
curacy (90). Despite this remarkable precision, however, blood
miRNA profiling tends to produce equivocal results in the
context of schizophrenia, with biomarker candidates varying
across independent studies (91–93). While this variability may
arise from various cofounding effects, including differences in
the type of tissue, low sample size, and smoking-related
epigenetic effects (94), it may also mirror the disorder’s etio-
logical (and phenotypic) heterogeneity (95,96).
EPIGENETIC MODIFICATIONS AS MOLECULAR
SCARS OF ENVIRONMENTAL EXPOSURES
While certain epigenetic modifications in schizophrenia may
have a genetic origin (12,13,53,97), converging evidence sug-
gests that a substantial portion of epigenetic alterations may
be acquired through environmental factors (98–101). Hence,
epigenetic modifications in schizophrenia may represent mo-
lecular scars of exposures to certain environmental adversities,
especially when encountered during sensitive developmental
periods (102–106). Consistent with this notion, a recent study
showed that blood HDAC1 levels were increased in patients
with schizophrenia who had been exposed to early-life stress
as compared with patients with schizophrenia who had not
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been exposed to early-life stress exposure (62). A plethora of
findings derived from animal models, in which causal links
among environmental factors, epigenetic modifications, and
pathological traits can be studied against the background of
genetic homogeneity, provide additional evidence for the
lasting impact of environmental factors on the epigenetic
machinery (107). As summarized in Table S1, many of these
models are based on environmental factors implicated in the
etiology of schizophrenia and related disorders (108), including
exposure to prenatal or postnatal stress, inhibitors of fetal
neurogenesis, infectious and noninfectious maternal immune
activation (MIA) during pregnancy, gestational and postpartum
nutritional deficiencies or exposure to drugs of abuse and
toxicants, reduced postpartum maternal care, and chronic
cannabis intake during adolescence. Not only do these models
capture a broad spectrum of behavioral and neurobiological
alterations pertinent to schizophrenia and other psychotic
disorders, but they also show lasting abnormalities in various
epigenetic profiles (Table S1).
While these models are relevant for other brain disorders as
well (109), they contribute to our understanding of how expo-
sure to environmental factors in early life can change neuro-
developmental trajectories and cause long-term brain
dysfunctions implicated in schizophrenia (108,110) and
beyond (109). Within the context of schizophrenia, a key
feature of these models is that they allow epigenetic screens
against multiple and coexisting schizophrenia-related dys-
functions while incorporating the disease-relevant concept of
abnormal brain development under stringent experimental
conditions. Furthermore, they can be used to explore whether
pharmacological or nonpharmacological interventions target-
ing the epigenetic machinery are capable of attenuating ab-
normalities in brain development and functions (107,111–113).
Although exposure to distinct environmental factors can
induce a specific set of epigenetic alterations (Table S1), there
is also notable convergence between the epigenetic effects of
individual environmental (and genetic) factors. Epigenetic
remodeling of the gene regulatory region of GAD1, which en-
codes the 67-kDa isoform of the GABA-synthesizing enzyme
glutamic acid decarboxylase (GAD67), is an illustrative
example of such convergence (Figure 2). In animal models,
altered DNAm in the gene regulatory region of Gad1 and cor-
responding GAD67 expression deficits have been found
following exposure to various environmental adversities,
including exposure to MIA (114), maternal stress (112,115), and
low postpartum maternal care (116). Intriguingly, these epige-
netic and transcriptional changes correlate with the deficits in
sociability and working memory occurring after MIA (114),
emphasizing a possible functional impact of Gad1 promoter
remodeling on schizophrenia-relevant behavioral and cognitive
Figure 2. Convergence between environmental and genetic factors in methylation-related remodeling of the GAD1 gene regulatory region. (A) Schematic
illustration of a simplified version of the GAD1 gene regulatory and coding regions that encodes the 67-kDa isoform of GAD (GAD67) mRNA. The GAD1 gene
regulatory region contains numerous CpG islands that facilitate methylation at position 50 in the cytosine ring (5mC). (B) Several environmental factors,
including maternal stress during pregnancy, maternal immune activation during pregnancy, and low postpartum maternal care, can cause hypermethylation of
the GAD1 gene regulatory region. Hypermethylation of the GAD1 gene regulatory region can also be caused by certain genetic variants (e.g., rs3749034, a
schizophrenia-risk single nucleotide polymorphism). In schizophrenia and disease-relevant model systems, epigenetic remodeling of the GAD1 gene regu-
latory region further includes increased binding of DNMTs and MeCP2 at GAD1 promoter regions. Together, these epigenetic changes can lead to reduced
transcription of GAD67 mRNA, which in turn has been associated with impaired neuronal synchronization and inhibition and the subsequent emergence of
behavioral and cognitive deficits. DNMT, DNA methyltransferase; GAD67, glutamic acid decarboxylase; MeCP2, methyl-CpG binding protein 2; mRNA,
messenger RNA; TSS, transcription start site.
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functions. Taken together, experimental research in animal
models of early-life adversities suggests that various environ-
mental factors, which have each been implicated in the etiol-
ogy of schizophrenia and related disorders, can converge on
the same molecular pathways affecting GABAergic develop-
ment and functions (Figure 2).
Even though schizophrenia has been repeatedly associated
with reduced GAD67 expression in cortical and hippocampal
areas, it remains elusive whether this GABAergic deficit stems
from altered DNAm in the gene regulatory region of GAD1
(20,35,39,46,102,117). Several schizophrenia postmortem
studies, however, show altered expression and/or promoter
binding of enzymes that are critical for the maintenance of the
DNA methylation/demethylation equilibrium of cytosines
positioned within a CG context, including DNMTs, TET pro-
teins, and MeCP2 (118–121). In addition, other epigenetic
changes may contribute to GAD1 promoter remodeling in
schizophrenia as well, including reduced repressive chromatin-
associated DNAm at the promoter, decreased H3K4 trime-
thylation (a marker of active transcription), and changes in the
3D configuration of the linear sequence containing the GAD1
locus (20,119,122,123).
While exposure to environmental adversities may readily
contribute to epigenetically driven deficits in GABAergic gene
transcription (Figure 2), several gene variants appear to do so
as well (53,97,124,125). The latter effects are consistent with
the considerable genetic influence on schizophrenia risk (2,5).
Future studies are warranted, however, to explore how specific
environmental and genetic factors can have additive or inter-
active effects on molecular pathways affecting GABAergic
gene transcription in schizophrenia and related disorders.
EPIGENETIC MODIFICATIONS AS SOURCE OF
PHENOTYPIC VARIABILITY
Schizophrenia is known to be highly heterogeneous in terms of
both its clinical presentation and its etiology. Even though they
are practical for clinicians, the diagnostic systems currently
used are not well equipped to capture the clinical heteroge-
neity of the disorder(s) that Bleuler initially referred to as the
“group of schizophrenias” [see (126)]. The clinical heteroge-
neity of schizophrenia is also mirrored by the underlying ge-
netic risk, which appears to be polygenic and highly
heterogeneous. While both common and rare genetic variants
shape the risk of developing schizophrenia (3,4), the disorder’s
common genetic risk is usually indexed by the PRS, which
reflects the cumulative sum of risk-associated alleles at com-
mon variants across the entire genome (4).
Under certain conditions, the PRS of schizophrenia may be
useful for estimating individual disease risk (127), treatment
response (128), and certain symptoms (129), but it might not
be capable of fully seizing the biological basis of the disorder’s
clinical and etiological heterogeneity (71). For example, in a
recent brain imaging study, it was found that the PRS was
unrelated to the substantial brain structural heterogeneity
present in schizophrenia (130). These findings suggest that
brain variability in schizophrenia results from interactions be-
tween environmental and genetic factors that are not captured
by the PRS.
To what extent may epigenetic modifications contribute to
phenotypic heterogeneity in schizophrenia? We deem this a
very likely possibility for various reasons. First, environmental
factors can influence the phenotypic presentation of schizo-
phrenia even if they do not interact with common genetic risk
of the disorder. One example is prenatal exposure to infectious
or noninfectious MIA, which has been shown to influence
structural brain abnormalities and executive functioning in
schizophrenia (131,132). While direct involvement of epige-
netic modifications still awaits examination in these epidemi-
ological associations, findings from animal models show that
such modifications provide a key mechanism mediating the
effects of MIA on schizophrenia-related structural and func-
tional brain anomalies in the offspring (114,133,134) (see also
Table S1). Interestingly, the specificity of epigenetic modifica-
tions and behavioral abnormalities induced by MIA are
dependent on the precise prenatal stage at which MIA occurs
(133), highlighting that epigenetic variability mirrors phenotypic
variability, at least in the context of MIA. Second, genetic
variants that are not considered as common in the genetics of
schizophrenia may nevertheless be etiologically relevant and
contribute to phenotypic heterogeneity by interacting with
environmentally acquired epigenetic modifications. The inter-
action between DISC1 and adolescent stress exposure, which
is mediated by stress-induced epigenetic modifications in the
mesocortical dopamine system (135), is an illustrative example
of this notion. Third, in healthy subjects, the broad interindi-
vidual variability in PFC development and functions is mirrored
by variable epigenetic profiles, which partly interact with ge-
netic factors (136,137). Fourth, even if some epigenetic mod-
ifications can be stable and perpetuate across generations,
others are highly dynamic and reversible (138). The latter not
only provides a rationale for epigenetically acting treatments
(111–113,139) but also provides a parsimonious explanation
for the variable and often irreproducible epigenetic findings in
schizophrenia (Tables 1 and 2). Taken together, epigenetic
modifications not only may help to explain missing heritability
in schizophrenia but also are a likely source of the disorder’s
phenotypic heterogeneity (Figure 3).
LIMITATIONS AND FUTURE DIRECTIONS
Even though the evidence for a role of abnormal epigenetic
processes in schizophrenia has rapidly accumulated over
recent years (140), there is as yet no clear picture of the precise
disease mechanisms involved. Indeed, different genome-wide
studies have limited overlap in terms of their results, and these
unbiased approaches could replicate only a small fraction of
the initial findings that were obtained from targeted (hypothe-
sis-driven) epigenetic studies. The lack of reproducibility is
most likely accounted for by a number of factors, including
small sample size and study population bias (141), influence of
chronic pharmacotherapy (142), and other confounders such
as smoking (143), methodological differences in epigenetic
screening (144), and heterogeneity of cell populations studied
(145). The latter has emerged as an important source of data
variability at both the gene transcriptional and epigenetic levels
(145), which in turn can mask diagnostic differences or lead to
spurious and irreproducible findings. Accounting for cell
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heterogeneity in epigenetic studies will require the imple-
mentation of single-cell technologies (146) and/or the use of
statistical methods that compute the relative proportions of
cell types from heterogeneous bulk tissues (147). The estab-
lishment of large databases and publicly available resources of
multidimensional genomic and epigenetic data obtained from
tissue-specific and cell type–specific samples, such as those
provided by the PsychENCODE initiative (68), will critically help
unravel the complex nature of genetic and epigenetic abnor-
malities in schizophrenia and other chronic brain disorders.
Such initiatives also underline the importance of incorporating
multiple and coexisting epigenetic anomalies in molecular
disease models of schizophrenia and related disorders rather
than relying on single genes such as GAD1 (Figure 3). Indeed,
similar to the polygenic architecture of schizophrenia
(2,5,127–129), a multitude of genes are likely to be epigeneti-
cally dysregulated in this disorder and in response to envi-
ronmental risk factors such as prenatal infection (133).
Most of the available epigenetic findings in schizophrenia
are based on analyses of postmortem brain samples, which
imposes the additional challenge of retrieving a reliable patient
history or antemortem diagnosis (148). The use of postmortem
samples also precludes the identification of dynamic changes
in epigenetic signatures that may occur in response to certain
clinical manifestations (e.g., acute exacerbation of psychotic
symptoms) or pharmacological treatments. Another limitation
of postmortem analyses is that they are unlikely to provide a
satisfactory answer to the question of whether epigenetic
anomalies are the cause or consequence of the disease.
Addressing this question in the context of schizophrenia war-
rants the use of longitudinal studies in which epigenetic sig-
natures can be followed-up in the same subjects from
premorbid and high-risk states to the eventual onset of full-
blown psychosis. Such longitudinal investigations, however,
will require the use of easily accessible tissues such as pe-
ripheral blood, saliva, and olfactory epithelium (149). Even if
epigenetic signatures in peripheral tissues might not neces-
sarily capture disease-associated epigenetic changes occur-
ring in the CNS (Tables 1 and 2), they can provide valuable
information regarding the clinical course of schizophrenia,
including conversion from a high-risk state to first-onset psy-
chosis (50). The complementary use of animal models will
further aid the interpretation of epigenetic findings obtained
from longitudinal studies in humans. Indeed, not only do ani-
mal models allow for a comparison of epigenetic signatures in
peripheral and CNS tissues at various stages of development
(133), but they also enable experimental testing of target se-
quences affected by chromatin alterations and their effects on
brain development and functions (150).
CONCLUSIONS
Despite the current limitations in the field, it is increasingly
recognized that epigenetic modifications may play a critical
Figure 3. Hypothetical model of the epigenetic influence on phenotypic trait variability. (A) Using the bean machine (Galton Board) as a simplified metaphor
for the specification of developmental trajectories, each developmental step is influenced by stochastic events occurring at distinct stages of development.
With the pegs representing developmental specification nodes, developmental steps can bounce either left or right when hitting the pegs. The phenotypic traits
associated with the developmental trajectories are spread according to a certain probability distribution. The current example shows a normal distribution of
phenotypic traits, which would occur when running a large number of identical balls through a leveled device with unbiased pegs. (B) In this hypothetical
model, environmentally and/or genetically driven epigenetic modifications targeting the pegs (i.e., the developmental specification nodes) can bias them
toward one direction, which in turn changes the probability distribution of the eventual phenotypic traits. Note that the influence of epigenetic modifications on
biasing the developmental trajectories would depend on its developmental timing and its specificity as well as on the nature of the developmental specification
node it targets (not shown). (C) Pharmacological or nonpharmacological interventions targeting epigenetic modifications at accessible developmental
specification nodes may reshape the probability distribution of phenotypic traits.
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role in the etiology and pathophysiology of schizophrenia.
Recent findings suggest that certain schizophrenia risk loci can
influence stochastic variation in gene expression through
epigenetic processes, highlighting the intricate interaction
between the genetic control and epigenetic control of devel-
opmental trajectories in schizophrenia. In addition, a sub-
stantial portion of epigenetic alterations in schizophrenia may
be acquired through environmental factors and remain stable
as molecular scars. Some of these scars may influence brain
functions throughout the entire lifespan and may even be
transmitted across generations via epigenetic germline inheri-
tance (see Supplement). Moreover, epigenetic modifications
are a plausible molecular source of phenotypic heterogeneity
and offer a target for therapeutic interventions. The further
elucidation of epigenetic modifications may thus increase our
knowledge regarding schizophrenia’s heterogeneous etiology
and pathophysiology and, in the long term, may advance
personalized treatments through the use of biomarker-guided
epigenetic interventions.
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